Sequoia Financial Advisors LLC Acquires 805 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Sequoia Financial Advisors LLC boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 0.7% in the third quarter, Holdings Channel reports. The firm owned 112,380 shares of the company’s stock after purchasing an additional 805 shares during the period. Sequoia Financial Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $2,025,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Raymond James & Associates raised its holdings in shares of Teva Pharmaceutical Industries by 25.1% during the third quarter. Raymond James & Associates now owns 1,020,719 shares of the company’s stock worth $18,393,000 after acquiring an additional 204,775 shares during the period. Blue Trust Inc. raised its position in Teva Pharmaceutical Industries by 40.1% during the third quarter. Blue Trust Inc. now owns 14,619 shares of the company’s stock worth $263,000 after acquiring an additional 4,185 shares in the last quarter. Claro Advisors LLC acquired a new stake in Teva Pharmaceutical Industries in the third quarter valued at $52,000. Creative Planning grew its position in shares of Teva Pharmaceutical Industries by 4.5% in the 3rd quarter. Creative Planning now owns 42,815 shares of the company’s stock valued at $772,000 after acquiring an additional 1,863 shares during the period. Finally, Ritholtz Wealth Management boosted its stake in shares of Teva Pharmaceutical Industries by 269.5% during the 3rd quarter. Ritholtz Wealth Management now owns 41,643 shares of the company’s stock worth $750,000 after acquiring an additional 30,374 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $18.25 on Friday. The stock has a market capitalization of $20.67 billion, a P/E ratio of -44.50, a price-to-earnings-growth ratio of 1.32 and a beta of 0.88. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 2.52. The firm’s fifty day simple moving average is $18.02 and its two-hundred day simple moving average is $16.73. Teva Pharmaceutical Industries Limited has a 12 month low of $8.10 and a 12 month high of $19.08.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.03. The business had revenue of $4.16 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. As a group, analysts predict that Teva Pharmaceutical Industries Limited will post 2.33 EPS for the current year.

Analyst Upgrades and Downgrades

TEVA has been the topic of several research analyst reports. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Wednesday, July 10th. JPMorgan Chase & Co. upped their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday. UBS Group raised their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Jefferies Financial Group boosted their target price on shares of Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

Insider Activity

In other news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the transaction, the insider now directly owns 45,060 shares in the company, valued at $777,285. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.